UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 ACT OF 1934 For the fiscal period ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41340 KLOTHO NEUROSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 86-2727441 (I.R.S. Employer Iden ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 ACT OF 1934 For the fiscal period ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41340 KLOTHO NEUROSCIENCES, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpora ...

☒ Annual Report Pursuant To Section 13 or 15(d) Of The Securities Exchange Act Of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) (Exact name of registrant as specified in its charter) | Delaware | 74-2963609 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) | 100 Park Ave., 23 Floor For the fiscal year ended December 31, 2024 New York, NY 10017 or ☐ Transition Report Pursuant To Sec ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ________ TO ________ COMMISSION FILE NUMBER 001-41304 VALUENCE MERGER CORP. I (Exact name of registrant as specified in its charter) | Cayman Islands | N/A | | --- | --- | | ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ________ TO ________ COMMISSION FILE NUMBER 001-41304 VALUENCE MERGER CORP. I (Exact name of registrant as specified in its charter) | Cayman Islands | N/A | | --- | --- | | ...

Financial Performance - Celcuity reported a net loss of approximately $111.8 million for the year ended December 31, 2024, compared to a net loss of $63.8 million for 2023[314]. - The net loss for the year ended December 31, 2024, was $111.8 million, a 75% increase from the previous year[323]. - Net cash used in operating activities was approximately $83.5 million for the year ended December 31, 2024, compared to $53.8 million in 2023[345][346]. - Net cash used in investing activities for 2024 was approximately $63.1 million, significantly higher than $5.0 million in 2023[347][348]. - Net cash provided by financing activities for 2024 was approximately $138.4 million, up from $64.9 million in 2023[349][350]. - The company raised approximately $369.0 million in net proceeds through equity securities and convertible notes from inception through December 31, 2024[330]. - As of December 31, 2024, Celcuity had cash and cash equivalents of approximately $235.1 million and an accumulated deficit of approximately $271.9 million[314]. - As of December 31, 2024, the company had cash and cash equivalents of approximately $22.5 million and short-term investments of $212.6 million[330]. - The Company believes its current cash and available borrowings will be sufficient to finance clinical development activities through 2026[342]. - The Company may seek additional capital to finance future expenditures and operations, which could result in dilution to existing shareholders[343]. Research and Development - Gedatolisib has been administered to 492 patients across eight clinical trials, with 129 patients receiving it as a single agent[299]. - In the Phase 1b clinical trial, the overall response rate (ORR) for treatment-naïve patients was 85%, while the ORR for patients who received prior hormonal therapy ranged from 36% to 77%[302]. - The median progression-free survival (PFS) for treatment-naïve patients receiving gedatolisib combined with palbociclib plus letrozole was 48.6 months[303]. - The VIKTORIA-1 Phase 3 clinical trial is fully enrolled for the PIK3CA wild-type cohort, with topline data expected in Q2 2025[311]. - The VIKTORIA-2 Phase 3 trial is set to enroll its first patient in Q2 2025, evaluating gedatolisib in combination with fulvestrant and a CDK4/6 inhibitor[312]. - The FDA approved the clinical development of gedatolisib in combination with Nubeqa® for metastatic castration-resistant prostate cancer in mid-2023[307]. - The Phase 1b/2 study CELC-G-201 is currently enrolling patients with mCRPC, with initial data expected by the end of Q2 2025[309]. - Gedatolisib's unique mechanism of action targets all Class I isoforms of PI3K and both mTOR complexes, potentially overcoming limitations of existing therapies[294]. - The Company expects to incur increased research and development expenses as it continues to develop gedatolisib and manage multiple clinical trials[341]. - The company plans to increase research and development expenses to support ongoing clinical trials, including VIKTORIA-1 and VIKTORIA-2[325]. Expenses - Research and development expenses for the year ended December 31, 2024, were approximately $104.2 million, an increase of 72% compared to 2023[324]. - General and administrative expenses for the year ended December 31, 2024, totaled $9.1 million, reflecting a 61% increase from 2023[326]. - Interest expense for the year ended December 31, 2024, was $10.3 million, up 93% compared to 2023, primarily due to increased debt[328]. - Interest income for the year ended December 31, 2024, was $11.8 million, representing a 51% increase compared to 2023[329]. - The Company anticipates future increases in general and administrative expenses due to potential commercialization of gedatolisib and expanding infrastructure[327]. - The Company anticipates increased sales and marketing expenses as it commercializes gedatolisib[341]. Debt and Financing - The company entered into an Amended and Restated Loan and Security Agreement on May 30, 2024, with a total principal amount of up to $180 million[335]. - The Company recognized a Final Fee of $4.5 million as additional debt principal on May 30, 2024[338]. - The Company issued 103,876 warrants with an exercise price of $14.84 per share, with a relative fair value of approximately $1.2 million[340].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 29, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 333-233233 BT BRANDS, INC. (Exact name of registrant as specified in its charter) Wyoming 90-1495764 (State or other jurisdiction of incorporation or organization) 10701 Wayzata Blvd S ...

Exhibit 99.1 INTERACTIVE STRENGTH INC. Interactive Strength Inc. (Nasdaq: TRNR) Reports Fourth Quarter & Year-End 2024 Results Company Delivers Quarterly Revenue of $2.4 Million as Projected or $5.4 Million for full-year 2024 Quarterly Net Loss and Earnings per Diluted Share of $5.8 Million and $7.26 Quarterly Adjusted EBITDA Loss of $1.9 Million Reflects 42% Improvement YOY and 19% Sequentially Stockholders' Equity Was $7.1 Million at Year End Pending Acquisitions Remain on Track; TRNR Expects More than $5 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37997 SACHEM CAPITAL CORP. (Exact name of registrant as specified in its charter) New York 81-3467779 State or othe ...

Exhibit 99.1 Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights SAN DIEGO, March 31, 2025 — (Business Wire) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today reported its fourth quarter and full-year 2024 operating and financial results and reviewed recent business highlights. "Calidi continues to make great progress on all thre ...